Silence Therapeutics (SLN) Payables (2018 - 2026)
Silence Therapeutics (SLN) posted Payables of $10.4 million for Q1 2026, down 22.38% sequentially from $13.4 million in Q4 2025, and down 44.89% YoY from $18.8 million in Q1 2025.
Silence Therapeutics (SLN) Payables (2018 - 2026) Analysis & Trends
Silence Therapeutics has reported Payables for 9 years, with the latest figure at $10.4 million in Q1 2026.
- Quarterly Payables fell 44.89% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (down 44.89% YoY) and the FY2025 annual result came in at $13.4 million, down 18.56% from the prior year.
- Payables retreated to $10.4 million in Q1 2026 per SLN's latest filing, from $13.4 million in the prior quarter.
- Over five years, Payables peaked at $18.8 million in Q1 2025 and troughed at $10.4 million in Q1 2026.
- A 5-year average of $15.1 million and a median of $15.1 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2024 and 2026: Payables advanced 6.31% in 2024, then slumped 44.89% in 2026.
- Over 5 years, Payables stood at $14.8 million in 2022, then increased by 4.11% to $15.4 million in 2023, then advanced by 6.31% to $16.4 million in 2024, then declined by 18.56% to $13.4 million in 2025, then slipped by 22.38% to $10.4 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $10.4 million, $13.4 million, and $17.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 12.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.61 Mn |
| Mar 31, 2026 | 10.37 Mn |
| Dec 31, 2025 | 13.36 Mn |
| Sep 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 14.31 Mn |
| Mar 31, 2025 | 18.81 Mn |
| Dec 31, 2024 | 16.40 Mn |
| Dec 31, 2023 | 15.43 Mn |
| Dec 31, 2022 | 14.82 Mn |
| Dec 31, 2021 | 14.54 Mn |
| Dec 31, 2020 | 10.82 Mn |
| Dec 31, 2019 | 8.86 Mn |
| Dec 31, 2018 | 4.93 Mn |